The 2021 Suzhou Hematology Summit, co-sponsored by the National Clinical Research Center for Hematological Diseases, the First Affiliated Hospital of Soochow University and the Jiangsu Institute of Hematology, was held in Suzhou on October 8, 2021. Since its inception in 2008, the Suzhou Hematology Summit has been successfully held for 13 sessions so far, sharing academic frontier progress for many hematology colleagues and well-known scholars in the field of hematology, and has now become an important event in the field of hematology in China.
Speech session
The opening ceremony of the conference was presided over by Professor Wu Depei of the First Affiliated Hospital of Soochow University.
Professor Wu Depei of the First Affiliated Hospital of Soochow University
Academician Ruan Changgeng of the First Affiliated Hospital of Soochow University first expressed his gratitude and welcome to all the experts who came to the meeting, hoping that all hematologists would "not forget their original intentions, keep in mind the mission", continue to deepen their cultivation in the field of hematology, and make greater contributions.
Academician Ruan Changgeng of the First Affiliated Hospital of Soochow University
Professor Chen Weichang, Member of the Standing Committee of the Party Committee and Vice President of Soochow University and Secretary of the Party Committee of the First Affiliated Hospital of Soochow University, then delivered a speech. Professor Chen Weichang said that the Suzhou Hematology Summit has now become an important platform for academic exchanges in hematology, and the success of the Suzhou Hematology Summit is inseparable from the support of your hematology colleagues, and Professor Chen Weichang expressed his sincere thanks to all colleagues on behalf of the First Affiliated Hospital of Soochow University. It is hoped that the successful holding of the Suzhou Hematology Summit will further promote the academic exchange of hematology in the country, and I wish the Suzhou Hematology Summit a complete success.
Professor Chen Weichang, Member of the Standing Committee of the Party Committee and Vice President of Soochow University, Secretary of the Party Committee of the First Affiliated Hospital of Soochow University
Vice Mayor Cao Houling of Suzhou Municipal People's Government then delivered a speech, and Vice Mayor Cao Houling, on behalf of Suzhou Municipal People's Government, congratulated all experts and scholars on the smooth convening of the Suzhou Hematology Summit, and expressed sincere greetings to all guests. I hope that this Suzhou Hematology Summit will, as always, be a platform for academic exchanges in hematology and promote the progress of hematology development.
Vice Mayor of Suzhou Municipal People's Government Cao Houling
Professor Ma Jun, Chairman of the Supervisory Board of the Chinese Society of Clinical Oncology (CSCO) and Chairman of the China Anti-Leukemia Alliance, then congratulated the success of the Suzhou Hematology Summit and wished the Suzhou Hematology Summit a complete success.
Professor Ma Jun, Chairman of the Supervisory Board of the Chinese Society of Clinical Oncology (CSCO) and Chairman of the China Anti-Leukemia Alliance
Professor Huang Xiaojun, chairman of the ninth hematology branch of the Chinese Medical Association and president of the Hematologist Branch of the Chinese Medical Doctor Association, said that under the efforts of hematologists across the country in the past few decades, the development of Chinese hematology has achieved considerable results, and hopes that the spirit of "bearing the motherland in mind and serving the people" can be continuously inherited.
Professor Huang Xiaojun, Chairman of the Ninth Hematology Branch of the Chinese Medical Association and President of the Hematologist Branch of the Chinese Medical Doctor Association
Chen Zhu, vice chairman of the Standing Committee of the National People's Congress and academician of the Chinese Academy of Sciences, expressed warm congratulations on the convening of the Suzhou Hematology Summit through video, and expressed sincere greetings to the experts who participated in the meeting.
Vice Chairman of the Standing Committee of the National People's Congress
Academician Chen Zhu of the Chinese Academy of Sciences
In the course of decades of development of Chinese hematology, there are many precious literary and historical materials worth cherishing, and there are also many abstract conceptual knowledge that needs to be promoted to the masses. To this end, led by the Hematology Branch of the Chinese Medical Association, after 1 year of preparation and construction, the China Hematology Museum was officially completed in Suzhou, and the inauguration ceremony of the China Hematology Museum was held at the Suzhou Hematology Summit.
Inauguration ceremony of the China Museum of Hematology
Hematopoietic stem cell transplantation is an important therapeutic means to cure hematological tumors, and hematopoietic stem cell transplant data is an important cornerstone for clinical research. In order to promote the systematic and standardized management of hematopoietic stem cell transplantation data in China. The Hematology Branch of the Chinese Medical Association organized the preparation of the "Standard Dataset of Hematopoietic Stem Cell Transplantation (2021 Edition)" and officially released it at the meeting.
Publication ceremony of the Standard Dataset for Hematopoietic Stem Cell Transplantation (2021 Edition).
Academic presentation session
Academician Wang Guangji of China Pharmaceutical University first gave a speech on the topic of "Pharmacoplasty of Living Cell Drugs - Efficacy and Druggability". Academician Wang Guangji first introduced the research status of living cell drugs, and the treatment of malignant hematological tumors has gradually entered the era of living cell drugs represented by chimeric antigen receptor t cell (car-t) immunotherapy and stem cell therapy. It is necessary to establish a preclinical pharmacokinetic research system for live cell drugs, elucidate the in vivo processes and pharmacodynamic mechanisms of cell drugs through pharmacokinetic studies, and promote clinical transformation. Academician Wang Guangji also said that there are still various scientific problems in the standardized preparation of living cell drugs, and it is necessary to establish a full-chain, closed-loop quality control system to ensure the safe use of living cell drugs.
Academician Wang Guangji of China Pharmaceutical University
Academician Chen Saijuan of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, then introduced the basic and clinical research progress of acute promyelocytic leukemia (apl) online. APL currently uses precision therapy based on molecular typing and risk stratification. The results of the apl 2012 clinical study involving 22 centers in China showed that chemotherapy could be replaced with arsenic in consolidation therapy for low- and moderate-risk patients, and chemotherapy could be reduced in high-risk patients. The 7-year disease-free survival (dfs) rate of arsenic combined with the all-trans retinoid (atra) regimen was 95.7%. Precision therapy under risk stratification can reduce toxic side effects and improve the quality of life of APL patients. In addition, by integrating the molecular markers of NRAS and gene expression profiling, the APL standard-risk and high-risk dichotomy was established, which made the prognostic prediction of APL more accurate. This new stratification method provides more reliable and objective treatment guidance for the clinical use of apl.
Academician Chen Saijuan of Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, introduced the pathogenesis of apl molecules
Academician Zhan Qimin of Peking University then gave a speech on the theme of "Scientific and Technological Innovation Helps the Development of Precision Medicine oncology". Academician Zhan Qimin said that the development of modern medicine has increased its dependence on scientific and technological progress, paying more attention to the cross-integration of multiple disciplines, and is inseparable from medical humanities. Precision therapy has rapidly emerged in the field of oncology in recent years, with great potential, but it also faces huge challenges. Academician Zhan Qimin said that in order to further help the development of precision tumor therapy, it is necessary to establish a large-scale biological sample bank and collect and use big data through the improvement of relevant laws and regulations.
Academician Zhan Qimin of Peking University
Dr. Zhao Renbin of Beijing Nuocheng Jianhua Pharmaceutical Technology Co., Ltd. then introduced the new progress of B-cell lymphoma from the perspective of drug research and development. Dr. Zhao Renbin said that in recent years, immunotherapy drugs represented by monoclonal antibodies, bispecific antibodies, and antibody drug conjugates, targeted therapeutic drugs represented by btk inhibitor osbutinib and bcl-2 inhibitor Venequera, and cell therapy products represented by car-t therapy have made great progress, bringing changes to the pattern of lymphoma treatment. The combined use of multi-target and multi-strategy has a potential mechanism to reduce toxicity and improve efficacy, and it is necessary to further strengthen the use of clinical combinations of various mechanism drugs.
Dr. Zhao Renbin of Beijing Nuocheng Jianhua Pharmaceutical Technology Co., Ltd
Professor Peter Hillmen of the University of Leeds concluded by introducing the research advances of BTK inhibitors in chronic lymphocytic leukemia (CLL). Professor Peter Hillmen said that the new targeted drugs have gradually replaced the position of immunochemotherapy in relapsing refractory CLL; whether it is a btk inhibitor or a fixed course of Venequera combined with anti-CD20 monoclonal antibody regimen has obtained good efficacy in CLL; in addition to ibutinib, zebutinib, acalabrutinib and other btk inhibitors have also obtained considerable efficacy in CLL; currently related studies are exploring the efficacy of a variety of targeted drugs combined regimen in CLL. It is expected to achieve the therapeutic goal of eliminating micro residual disease (MRD) for patients with CLL.
Peter Hillmen Professor, University of Leeds
summary
The successful opening of the Suzhou Hematology Summit shared the latest frontier progress in hematology for the national hematologists, and further promoted the academic exchange of hematology in China. Many experts and scholars made wonderful speeches on hot topics in hematology, which made the hematologists attend the meeting gain a lot. Many hematologists will continue to inherit the spirit of serving patients with blood diseases, so that the development of Hematology in China will continue to innovate and create more brilliant.